245 related articles for article (PubMed ID: 26091007)
1. Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
Chen R; Huang Y; Cai X; Xie L; He D; Zhou L; Xu C; Gao X; Ren S; Wang F; Ma L; Wei Q; Yin C; Tian Y; Sun Z; Fu Q; Ding Q; Zheng J; Ye Z; Ye D; Xu D; Hou J; Xu K; Yuan J; Gao X; Liu C; Pan T; Sun Y;
PLoS One; 2015; 10(6):e0130308. PubMed ID: 26091007
[TBL] [Abstract][Full Text] [Related]
2. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
4. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
Nan LB; Yin XT; Gao JP
Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
[TBL] [Abstract][Full Text] [Related]
5. Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0-10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium.
Chen R; Xie L; Cai X; Huang Y; Zhou L; Ma L; Gao X; Xu C; Ren S; Shao P; Xu D; Xu K; Ye Z; Liu C; Ye D; Lu L; Fu Q; Hou J; Yuan J; He D; Zhou T; Wang F; He B; Sun Y;
Asian J Urol; 2015 Apr; 2(2):107-113. PubMed ID: 29264128
[TBL] [Abstract][Full Text] [Related]
6. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
7. Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population.
Na R; Wu Y; Xu J; Jiang H; Ding Q
PLoS One; 2013; 8(6):e67585. PubMed ID: 23825670
[TBL] [Abstract][Full Text] [Related]
8. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.
Vessella RL; Lange PH; Partin AW; Chan DW; Sokoll LJ; Sasse EA; Crawford ED
Urology; 2000 Jun; 55(6):909-14. PubMed ID: 10840107
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
10. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
Erol B; Gulpinar MT; Bozdogan G; Ozkanli S; Onem K; Mungan G; Bektas S; Tokgoz H; Akduman B; Mungan A
Kaohsiung J Med Sci; 2014 Nov; 30(11):545-50. PubMed ID: 25458043
[TBL] [Abstract][Full Text] [Related]
11. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
12. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR
Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089
[TBL] [Abstract][Full Text] [Related]
13. Effect of percent free prostate-specific antigen measurement on improving the specificity of serum prostate-specific antigen testing in Taiwanese patients.
Liao CH; Liu SP; Pu YS; Huang CY; Yu HJ; Chen J
J Formos Med Assoc; 2001 Feb; 100(2):113-9. PubMed ID: 11393098
[TBL] [Abstract][Full Text] [Related]
14. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
15. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Yoneyama T; Ohyama C; Hatakeyama S; Narita S; Habuchi T; Koie T; Mori K; Hidari KI; Yamaguchi M; Suzuki T; Tobisawa Y
Biochem Biophys Res Commun; 2014 Jun; 448(4):390-6. PubMed ID: 24814705
[TBL] [Abstract][Full Text] [Related]
16. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
17. Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values.
Yilmaz H; Ciftci S; Yavuz U; Ustuner M; Saribacak A; Dillioglugil O
Kaohsiung J Med Sci; 2015 Jun; 31(6):315-9. PubMed ID: 26043411
[TBL] [Abstract][Full Text] [Related]
18. Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.
Zhao R; Huang Y; Cheng G; Liu J; Shao P; Qin C; Hua L; Yin C
PLoS One; 2014; 9(9):e106933. PubMed ID: 25268808
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
20. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL.
Babaian RJ; Fritsche H; Ayala A; Bhadkamkar V; Johnston DA; Naccarato W; Zhang Z
Urology; 2000 Dec; 56(6):1000-6. PubMed ID: 11113747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]